Plain-English translation of NCT06440005 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a medication called , which is an antibody-drug conjugate — a type of therapy designed to attack cancer cells. The trial will give this medication to people with advanced cancers that have not responded to standard treatments, starting at lower doses and gradually increasing them to find the right balance between effectiveness and safety.
Many people with advanced cancers run out of effective treatment options when standard therapies stop working. This medication targets a protein called TM4SF1 that appears on certain cancer cells, offering a new approach for patients who need additional options.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion on Day 1 of each cycle, with cycles repeating every 3, 6, or 9 weeks depending on your dose level. The first infusion takes 90 minutes, the second takes 60 minutes, and subsequent infusions take 30 minutes. You can continue treatment as long as the medication is helping and you are tolerating it well, and you will have follow-up safety check-in phone calls for up to 90 days after your last dose.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States